DEF: Medpace Holdings Sets Date for 2025 Annual Stockholders Meeting, Outlines Proposals

Medpace Holdings will hold its 2025 Annual Meeting of Stockholders virtually on May 16, 2025, to vote on director elections, auditor ratification, executive compensation, an incentive award plan, and a stockholder proposal.

Summary

• Medpace Holdings, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 16, 2025.
• Stockholders of record as of March 20, 2025, are entitled to vote.
• The meeting will address the election of August J. Troendle and Dani S. Zander as Class III Directors.
• Stockholders will vote to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory vote will be held to approve the compensation of the named executive officers.
• Stockholders will vote on approving the Medpace Holdings, Inc. 2016 Amended and Restated Incentive Award Plan.
• A stockholder proposal regarding the implementation of simple majority voting will be considered.
• The Board of Directors recommends voting FOR the election of directors, ratification of the accounting firm, approval of executive compensation, and approval of the incentive award plan.
• The Board recommends voting AGAINST the stockholder proposal regarding simple majority voting.
• The proxy statement and the Company's Annual Report to Stockholders for the year ended December 31, 2024, were released on or about April 2, 2025.
• The company exceeded its financial guidance for fiscal year 2024 with respect to GAAP net income, EBITDA and diluted earnings per share (GAAP).
• The company did not exceed its financial guidance for fiscal year 2024 with respect to revenue.
• Revenue for the year ended December 31, 2024, increased 11.8% to $2,109.1 million, compared to $1,885.8 million for the year ended December 31, 2023.
• GAAP net income for the full year 2024 was $404.4 million, an increase of 43.0%, compared to GAAP net income of $282.8 million for the year ended December 31, 2023.
• GAAP net income per diluted share for the full year 2024 was $12.63, an increase of 42.2%, compared to GAAP net income per diluted share of $8.88 for the year ended December 31, 2023.
• EBITDA for the full year 2024 increased 32.5% to $480.2 million compared to $362.5 million for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial performance, particularly in net income and EBITDA growth. The focus on aligning executive compensation with company performance and shareholder value also contributes to a favorable sentiment.

Positives

• The company exceeded its financial guidance for fiscal year 2024 with respect to GAAP net income, EBITDA and diluted earnings per share (GAAP).
• Revenue for the year ended December 31, 2024, increased 11.8% to $2,109.1 million, compared to $1,885.8 million for the year ended December 31, 2023.
• GAAP net income for the full year 2024 was $404.4 million, an increase of 43.0%, compared to GAAP net income of $282.8 million for the year ended December 31, 2023.
• GAAP net income per diluted share for the full year 2024 was $12.63, an increase of 42.2%, compared to GAAP net income per diluted share of $8.88 for the year ended December 31, 2023.
• EBITDA for the full year 2024 increased 32.5% to $480.2 million compared to $362.5 million for the year ended December 31, 2023.

Negatives

• The company did not exceed its financial guidance for fiscal year 2024 with respect to revenue.

Future Outlook

The Compensation Committee expects that as Company performance continues to achieve median and higher performance levels relative to its peer companies, it will seek to achieve and maintain compensation levels for NEOs at or above the 50th percentile going forward.

Industry Context

The document highlights Medpace's position as a leading clinical contract research organization (CRO) and the competitive nature of the industry, emphasizing the importance of executive compensation in attracting and retaining talent.

Comparison to Industry Standards

• The Compensation Committee benchmarks the Companys total direct compensation (i.e., base salary, short-term incentive compensation plus long-term incentive compensation) against the 50th percentile of total direct compensation paid by its peer group, with the goal to be at a level that is plus or minus 20% of the 50th percentile.
• The peer group consists of Agilent Technologies, Inc., ICON plc, Bio-Techne Corporation, IQVIA Holdings Inc., Bruker Corporation, Labcorp Holdings Inc., Catalent, Inc., Quest Diagnostics Inc., Charles River Laboratories, Revvity, Inc., Fortrea Holdings Inc., and Sotera Health Company.

Related Party Transactions

• Certain executives and employees of the Company, including our Chief Executive Officer, are members of LIBs board of managers and/or have equity investments in LIB.
• Certain executives and employees of the Company, including our Chief Executive Officer, are members of CinRxs board of managers and/or have equity investments in CinRx, a biotech company.
• The Summit Hotel, located on the Medpace campus, is owned by our Chief Executive Officer.
• Medpace Investors is a noncontrolling stockholder and related party of the Company.
• The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by our Chief Executive Officer.
• The Company incurs expenses for travel services for company executives provided by a private aviation charter company controlled by our Chief Executive Officer.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• Employees are affected by the incentive award plan and executive compensation decisions.
• The company's performance and governance decisions impact its reputation and relationships with customers and suppliers.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The Board of Directors will consider the results of the advisory vote on executive compensation when making future decisions.
• The Compensation Committee expects to review and make determinations on Long-Term Equity Incentive Compensation grants for NEOs in conjunction with the review and determination of equity grants made more broadly to eligible employees within the Company.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Executive Compensation, Director Election, Incentive Award Plan, Auditor Ratification, Medpace Holdings